28.03.2013 - Japanese Otsuka and Danish Lundbeck have inked a US$825m co-development and co-marketing deal in Alzheimer's disease.
Under the terms of the agreement, the Copenhagen-based neurology specialist will grant Otsuka (Tokyo) co-development and co-commercialisation rights to its selective 5-HT6-receptor antagonist LU AE58054 in the US, Canada, East Asia, Japan, and major European pharma markets.
The Japanese company will pay US$150m upfront. Both companies will share the sales, development, and commercialisation costs. Lundbeck is also entitled to up to US$675m in milestones.
A pivotal clinical programme with Lu AE58054 enroling more than 2,500 patients with mild-to-moderate Alzheimer's disease is planned to be initiated later this year. Lu AE58054 will be tested as adjunct treatment to donepezil. Last May, Lundbeck reported that Lu AE58054 had met its primary endpoint in a 24-week clinical Phase II trial in 278 patients in the same setting as the confirmatory Phase III study.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more